Scarica l'app Stockscreener
33.12
2.03%
0.665
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$32.46
Aprire:
$32.23
Volume 24 ore:
43,850
Relative Volume:
0.76
Capitalizzazione di mercato:
$400.35M
Reddito:
$9.71M
Utile/perdita netta:
$-29.96M
Rapporto P/E:
-9.5187
EPS:
-3.48
Flusso di cassa netto:
$-14.79M
1 W Prestazione:
+4.84%
1M Prestazione:
+29.98%
6M Prestazione:
+40.82%
1 anno Prestazione:
+14.25%
Intervallo 1D:
$32.01
$33.75
Intervallo di 1 settimana:
$30.55
$33.75
Portata 52W:
$18.35
$35.00
Xoma Royalty Corp Stock (XOMA) Company Profile
Nome
Xoma Royalty Corp
Settore
Industria
Telefono
510-204-7239
Indirizzo
2200 POWELL STREET, EMERYVILLE, CA
Confronta XOMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
33.12 | 383.66M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.25 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.93 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.93 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.84 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.39 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | The Benchmark Company | Buy |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2021-09-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-06-29 | Iniziato | Aegis Capital | Buy |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-17 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-05 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2017-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2016-11-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-11 | Reiterato | Wedbush | Outperform |
| 2015-07-23 | Downgrade | Jefferies | Buy → Hold |
| 2015-07-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Ripresa | ROTH Capital | Buy |
| 2014-04-29 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-03-11 | Downgrade | MLV & Co | Buy → Hold |
| 2014-03-05 | Reiterato | Ladenburg Thalmann | Buy |
| 2013-10-31 | Reiterato | MLV & Co | Buy |
| 2013-05-09 | Reiterato | Ladenburg Thalmann | Buy |
| 2012-05-14 | Iniziato | Cowen & Co | Outperform |
| 2011-03-31 | Reiterato | MLV Capital | Buy |
| 2011-03-23 | Reiterato | RBC Capital Mkts | Outperform |
| 2011-01-06 | Reiterato | Ladenburg Thalmann | Buy |
| 2011-01-04 | Reiterato | Wedbush | Outperform |
Mostra tutto
Xoma Royalty Corp Borsa (XOMA) Ultime notizie
Mural Jumps on Partnership with XOMA - Baystreet.ca
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech - BioPharma Dive
Heatmap analysis for XOMA Royalty Corporation and competitorsJuly 2025 Summary & Reliable Volume Spike Alerts - Newser
Mural Oncology to be Acquired by XRA 5 - citybiz
Mural Oncology plc enters acquisition agreement with XRA 5 Corp (XOMA Royalty Corporation) - Arthur Cox LLP
Xoma adds fading Mural Oncology to portfolio of struggling biotechs - Fierce Biotech
XOMA Royalty To Acquire Mural Oncology - Nasdaq
XOMA Royalty Unit to Acquire Mural Oncology - MarketScreener
XOMA Royalty to acquire Mural Oncology for up to $2.24 per share - Investing.com
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - Yahoo Finance
WALTHAM, DUBLIN, EMERYVILLEMural Oncology agrees to acquisition by XOMA Royalty subsidiary - Investing.com
98% Premium: XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal - Stock Titan
Analyzing drawdowns of XOMA Royalty Corporation with statistical toolsMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Using Bollinger Bands to evaluate XOMA Royalty CorporationShort Setup & AI Enhanced Trade Execution Alerts - Newser
What Fibonacci levels say about XOMA Royalty Corporation reboundQuarterly Market Review & Trade Opportunity Analysis - Newser
What’s next for XOMA Royalty Corporation stock price2025 Big Picture & Free Daily Entry Point Trade Alerts - Newser
Analyzing recovery setups for XOMA Royalty Corporation investorsQuarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
XOMA Royalty Corporation stock retracement – recovery analysisPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Can a trend reversal in XOMA Royalty Corporation lead to recoveryJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - Newser
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15% - Yahoo Finance
Q3 EPS Estimates for XOMA Royalty Reduced by Leerink Partnrs - Defense World
What institutional flow reveals about XOMA Royalty CorporationWeekly Profit Report & Community Verified Trade Signals - Newser
XOMA Co. (NASDAQ:XOMAP) Short Interest Update - Defense World
Is XOMA Royalty Corporation stock a buy or sellTrade Entry Summary & Precise Trade Entry Recommendations - thegnnews.com
Leerink Partnrs Forecasts Higher Earnings for XOMA Royalty - Defense World
Custom watchlist performance reports with XOMA Royalty Corporation2025 Risk Factors & Expert Approved Trade Ideas - Newser
What the charts say about XOMA Royalty Corporation today2025 AllTime Highs & Consistent Return Strategy Ideas - Newser
Xoma Completes Merger with Turnstone Biologics Corp - TipRanks
Xoma Corp. Reports Strong Earnings Growth in 2025 - MSN
Xoma: Leerink Partners Reaffirms Buy Rating with $55 Target, Analyst Consensus at Moderate Buy with $62 Average Target - AInvest
We Think XOMA Royalty (NASDAQ:XOMA) Has A Fair Chunk Of Debt - 富途牛牛
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - MarketScreener
Leerink Partners reiterates Outperform rating on XOMA stock amid strong Q2 results - Investing.com Nigeria
XOMA (NASDAQ:XOMAO) Trading Up 0.4% – Here’s Why - Defense World
XOMA Royalty 2025 Q2 Earnings Declining Net Income Amid Revenue Growth - AInvest
Live market analysis of XOMA Royalty CorporationWeekly Risk Summary & Free Daily Entry Point Trade Alerts - Newser
XOMA Royalty Corp Surpasses Revenue Estimates with $13.1M Q2 Revenue, EPS Misses Expectations - AInvest
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - uk.finance.yahoo.com
XOMA Posts 39% Revenue Growth in Q2, Net Income Down 42.5% - AInvest
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
XOMA Royalty Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Will breakout in XOMA Royalty Corporation lead to full recoveryQuarterly Market Review & Weekly Return Optimization Plans - Newser
XOMA Royalty: A Biotech Royalty Aggregator with Explosive Growth Potential - AInvest
XOMA Royalty Corporation Reports Q2 2025 Financial Results - TradingView
XOMA Royalty Corp SEC 10-Q Report - TradingView
Lava Therapeutics shares rise 1.32% intraday after XOMA Royalty Corporation's acquisition of Turnstone Biologics Corp. - AInvest
Should you wait for a breakout in XOMA Royalty CorporationBuy Zone Strategy with Pattern Recognition - Newser
Evaluating XOMA Royalty Corporation with trendline analysisFree Conservative Entry for High Return Setup - Newser
Gold Royalty Corp. shares fall 3.25% intraday after Royalty Management Holding Corporation reported record second quarterly results for the period ended June 30, 2025. - AInvest
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics - GlobeNewswire
Xoma Royalty Corp Azioni (XOMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xoma Royalty Corp Azioni (XOMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hughes Owen | Chief Executive Officer |
May 19 '25 |
Option Exercise |
0.00 |
53,359 |
0 |
88,338 |
| Hughes Owen | Chief Executive Officer |
May 20 '25 |
Sale |
25.38 |
25,637 |
650,667 |
62,701 |
| BURNS THOMAS M. | SVP, Finance & CFO |
May 19 '25 |
Option Exercise |
0.00 |
17,773 |
0 |
33,045 |
| BURNS THOMAS M. | SVP, Finance & CFO |
May 20 '25 |
Sale |
25.38 |
10,482 |
266,033 |
22,563 |
| BVF PARTNERS L P/IL | 10% Owner |
May 16 '25 |
Sale |
27.10 |
392,723 |
10,642,793 |
1,267,545 |
| Sitko Bradley | Chief Investment Officer |
Apr 07 '25 |
Buy |
24.70 |
2,000 |
49,400 |
5,045 |
| LIMBER JOSEPH M | Director |
Apr 03 '25 |
Buy |
25.24 |
17,935 |
452,631 |
16,524 |
| LIMBER JOSEPH M | Director |
Apr 04 '25 |
Buy |
25.40 |
6,822 |
173,293 |
20,000 |
| LIMBER JOSEPH M | Director |
Apr 07 '25 |
Buy |
25.60 |
5,243 |
134,221 |
10,000 |
| Sitko Bradley | Chief Investment Officer |
Mar 31 '25 |
Buy |
21.04 |
1,245 |
26,201 |
11,484 |
0.94%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):